Elanco Animal Health (ELAN) Net Equity Issued and Repurchased (2020 - 2021)
Elanco Animal Health (ELAN) posted Net Equity Issued and Repurchased of $500.0 million for Q4 2021, down 59.02% sequentially from $1.2 billion in Q1 2020.
Elanco Animal Health (ELAN) Net Equity Issued and Repurchased (2020 - 2021) Analysis & Trends
Elanco Animal Health has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $500.0 million in Q4 2021.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $500.0 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $500.0 million (down 59.02% YoY) and the FY2022 annual result came in at $425.0 million, down 15.0% from the prior year.
- Net Equity Issued and Repurchased retreated to $500.0 million in Q4 2021 per ELAN's latest filing, from $1.2 billion in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $1.2 billion in Q1 2020 and troughed at $500.0 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.60 Bn | 42.64 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.50 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.66 Bn | 22.86 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.22 Bn | 19.55 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 700,000.00 |
| 7 | Neurocrine Biosciences | 15.69 Bn | 15.30 Bn | 935.80 Mn | 84.80 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.07 Bn | 9.91 Bn | - | - |
| 10 | Alkermes | 8.26 Bn | 7.60 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 500.00 Mn |
| Dec 31, 2021 | 500.00 Mn |
| Mar 31, 2020 | 1.22 Bn |
| Mar 31, 2020 | 1.22 Bn |